Navigation Links
Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product
Date:1/5/2012

BRIDGEWATER, N.J., Jan. 5, 2012 /PRNewswire/ -- Sanofi US today announced that the U. S. District Court in Massachusetts granted the company a preliminary injunction against a Synvisc-One® (hylan G-F 20) competitor product developed by Seikagaku Corporation. The ruling allows for a restricted launch of Seikagaku's product prior to a scheduled trial date in April, and prohibits Seikagaku from selling their product below the current average sales price for Synvisc-One.

(Logo:  http://photos.prnewswire.com/prnh/20110616/NY20158LOGO )

In its recent ruling, the Court found that Seikagaku was not likely to prevail at trial, which will focus on U.S. Patent 7,931,030.

"We are pleased that the Court recognized the strength of our '030 patent, which protects Genzyme's Synvisc-One® franchise," said Alison Lawton, Senior Vice President and General Manager of Sanofi's Biosurgery business. "We are also pleased that the Court took decisive steps to protect the market position that Genzyme earned through its research and development and product innovation."

Synvisc-One® has been the only single-injection viscosupplement for the treatment of osteoarthritis (OA) knee pain on the U.S. market since it was launched in the first quarter of 2009.  The market for such treatments is large, growing and underpenetrated; of the estimated 9 million eligible OA patients in the United States, only about 14 percent are currently treated with viscosupplements.

Sanofi's Biosurgery business, which markets a variety of products globally in the areas of osteoarthritis, postoperative adhesion prevention, and cell therapy, is focused on transforming disease management through innovative medical interventions.  It became part of Sanofi following the company's acquisition of Genzyme Corporation in 2011.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as Sanofi-aventis U.S. LLC. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.

Contacts:

US Communications
Kim Fox
+1-908-981-4851
Kimberly.Fox@sanofi.com

Investor Relations
Sebastien Martel
+ 33 153-774-543
sebastien.martel@sanofi-aventis.com


'/>"/>
SOURCE Sanofi
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
Breaking Medicine News(10 mins):